Cognition Therapeutics, Inc. (CGTX) Stock Forecast
CGTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $3.33 average of analyst targets
- Upside to target
- +356.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.07
- 52-week range
- $0.59 – $1.83
CGTX analyst ratings
3 analystsNumber of analysts at each rating.
CGTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CGTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.07 | −$0.06 | −$0.06 | −11.1% | 3 |
| Current fiscal year (2026) | −$0.30 | −$0.42 | −$0.20 | −$0.32 | +7.3% | 3 |
| Next fiscal year (2027) | −$0.22 | −$0.25 | −$0.19 | −$0.30 | +25.8% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CGTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
CGTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CGTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.07 | −$0.07 | −$0.07 | −$0.07 | −8.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.32 | −$0.30 | −$0.30 | −$0.30 | −$0.30 | −8.0% | 3 up · 0 down |
| Next fiscal year (2027) | −$0.28 | −$0.22 | −$0.22 | −$0.22 | −$0.22 | −20.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CGTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CGTX beat in 8 of 12.
What analysts expect from CGTX
3 analysts cover Cognition Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.33, 356.6% above the latest close of $0.73. Analysts expect earnings of −$0.30 per share for 2026, +7.3% from a year earlier. For 2027 the average estimate is −$0.22 per share. Cognition Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: CGTX income statement, CGTX key metrics, CGTX chart. See the CGTX stock overview for the latest quote and news.
CGTX forecast FAQ
What is Cognition Therapeutics's price target?
The average analyst price target for Cognition Therapeutics is $3.33, 356.6% above the latest close of $0.73.
Is Cognition Therapeutics a buy, hold or sell?
Of 3 analysts covering Cognition Therapeutics, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cognition Therapeutics's EPS forecast?
Analysts forecast −$0.30 per share for 2026 (range −$0.42 to −$0.20); for 2027 the estimate is −$0.22.
When does Cognition Therapeutics report earnings?
Cognition Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.07.
Does Cognition Therapeutics usually beat earnings estimates?
Cognition Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.